Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker. The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

the trastuzumab-binding epitope (597–626) and the pertuzumab-binding epitope (266–296). All four peptide sequences inhibited tumor cell proliferation. Although all four sequences were ...

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...